Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination
V Wetzl, E Schinner, F Kees, L Faerber… - Naunyn-schmiedeberg's …, 2017 - Springer
Renal fibrosis is an important factor for end-stage renal failure. However, only few
therapeutic options for its treatment are established. Zaprinast, a phosphodiesterase 5 …
therapeutic options for its treatment are established. Zaprinast, a phosphodiesterase 5 …
Effect of the phosphodiesterase-5 inhibitor zaprinast on ischemia-reperfusion injury in rats
AJ Polcari, AV Farooq, ME Woods, MS Ripsch… - Journal of …, 2013 - liebertpub.com
Purpose: The cardiac and renal protective effects of phosphodiesterase-5 (PDE-5) inhibitors
against ischemia-reperfusion injury have recently been demonstrated in animal studies. We …
against ischemia-reperfusion injury have recently been demonstrated in animal studies. We …
Fibrose-assoziierte Biomarker–Einfluss der Behandlung mit Serelaxin im murinen Nierenfibrose-Modell und prädiktiver Aussagewert in der pulmonalen Hypertonie
V Wetzl - 2017 - epub.uni-regensburg.de
Die Fibrose stellt aufgrund ihrer hohen Prävalenz in der Bevölkerung, der schlechten
Prognose für die Patienten, sowie der komplexen Pathophysiologie ein sehr wichtiges …
Prognose für die Patienten, sowie der komplexen Pathophysiologie ein sehr wichtiges …
[PDF][PDF] BIOASSAY-GUIDED FRACTIONATION AND ANTIHYPERTENSIVE PROPERTIES OF FRACTIONS AND CRUDE EXTRACTS OF
P BICALYCULATA - ACTA POLONIAE PHARMACEUTICA, 2015 - ptfarm.pl
Hypertension is an important public health issue in both developed and developing
countries due to its high incidence and morbidity. This has motivated researchers especially …
countries due to its high incidence and morbidity. This has motivated researchers especially …